PI
RIGL icon

Putnam Investments’s Rigel Pharmaceuticals RIGL Stock Holding History

Putnam Investments’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,573
Closed -$330K – 1197
2023
Q2 		$330K Sell
25,573
-799
-3% -$10.8K ﹤0.01% 1065
2023
Q1 		$348K Buy
+26,372
New +$419K ﹤0.01% 1050
2016
Q3 		– Sell
-29,102
Closed -$649K – 1336
2016
Q2 		$649K Buy
+29,102
New +$724K ﹤0.01% 1165

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Putnam Investments's RIGL Position: Q3 2023 in Review

Putnam Investments sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 25,573 shares — an estimated $330K sold.

Putnam Investments first reported a position in RIGL in Q2 2016 and held it in 3 quarters. The position peaked at $649K in Q2 2016. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

  • Putnam Investments reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Putnam Investments sold 25,573 Rigel Pharmaceuticals shares in Q3 2023, an estimated $330K.
  • Putnam Investments first reported a position in Rigel Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Putnam Investments's Rigel Pharmaceuticals position peaked at $649K in Q2 2016.
  • 106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Putnam Investments's 13F filing for Q3 2023, filed 14 Nov 2023.